News
Pelage Pharmaceuticals Advances Clinical Program with First Patients Dosed in Phase 2 Study for Hair Loss
Pelage Pharmaceuticals Advances Clinical Program with First Patients Dosed in Phase 2 Study for Hair Loss and GV-Led $14M Series A-1 NEWS PROVIDED BY Pelage Pharmaceuticals
Aug 13, 2024, 08:00 ET
Inclusive trial recruiting women and men with androgenetic alopecia to evaluate safety and preliminary efficacy of PP405, a topical treatment designed to reactivate dormant hair follicle stem cells
Trethera Receives $2M NIH Grant
Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced today that it was awarded a $2 million NIH Small Business Innovation Research (SBIR) grant for preclinical studies treating acute disseminated encephalomyelitis (ADEM), a neurologic disease principally of children. Trethera’s clinical stage and first-in-class drug, TRE-515, holds the only FDA Orphan Drug designation for ADEM.
Dr. Moustache and the Bubble Baby Disease: A CIRM Success Story
Dr. Moustache has done it again.
Another child has been treated for a deadly affliction known as the “bubble boy” disease. Dr. Moustache and his “magical team” did have a little help, courtesy of the people of California who put tens of millions of dollars into financing his cell and gene therapy.
Innovation Magazine Summer 2024 Edition
In this issue:
- A new partnership with UCLA Ventures
- Funding updates for TORL, Pelage Pharmaceuticals, UCLA Samueli, and ImmPACT Bio
- A trip to the UCLA Research Park
- Event wrap ups for MedTech, LABEST and UCLA Ventures dinner
and more
Biden administration proposal threatens innovative research
Biden administration proposal threatens innovative research at universities across the country
UCLA students transition between classes at the Westwood campus on September 27, 2022. (Photo by Dean Musgrove, Los Angeles Daily News/SCNG)
CrewLAB Raises $1.6M to Democratize Data & Technology for Endurance Sports Teams
CrewLAB Raises $1.6M to Democratize Data & Technology for Endurance Sports Teams
GV Backs Hair Loss Biotech out of UCLA with PhII set for mid-2024
Pelage Pharmaceuticals, a Los Angeles-based hair loss biotech based on research out of UCLA, has reeled in a $16.75 million Series A and plans to start a mid-stage trial later this year.
See full article below;